Blar i St. Olavs hospital på tidsskrift "BioDrugs"
Viser treff 1-1 av 1
-
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
(Peer reviewed; Journal article, 2020)Background - The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn’s disease ...